Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2

References

• Hemming AW, Berumen J, Mekeel K. Hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2016;20:703–720. doi:10.1016/j.cld.2016.06.00727742009
   PubMed Web of Science ®Google Scholar
• Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–2063. doi:10.1002/hep.2258019003900
   PubMed Web of Science ®Google Scholar
• Khalaf AM, Fuentes D, Morshid AI, et al. Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018;5:61–73. doi:10.2147/JHC.S15670129984212
   PubMed Web of Science ®Google Scholar
• Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2018;6:11–21. doi:10.2147/JHC30643759
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu X, Zheng X, Yao Y, Liu Q. PKM2 regulates Gli1 expression in hepatocellular carcinoma. Oncol Lett. 2014;8:1973–1979. doi:10.3892/ol.2014.244125289083
   PubMed Web of Science ®Google Scholar
• Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011;480:118–122. doi:10.1038/nature1059822056988
   PubMed Web of Science ®Google Scholar
• Azoitei N, Becher A, Steinestel K, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation. Mol Cancer. 2016;15:3. doi:10.1186/s12943-015-0490-226739387
   PubMed Web of Science ®Google Scholar
• Hoshino A, Hirst JA, Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem. 2007;282:17706–17711. doi:10.1074/jbc.M70009420017446165
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 2012;209:217–224. doi:10.1084/jem.2011148722271574
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–530. doi:10.1085/jgp.8.6.51919872213
   PubMedGoogle Scholar
• Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. doi:10.1186/1476-4598-12-15224298908
   PubMed Web of Science ®Google Scholar
• Liu T, Xia Y, Li J, et al. Shikonin attenuates concanavalin A-induced acute liver injury in mice via inhibition of the JNK pathway. Mediators Inflamm. 2016;2016:2748367. doi:10.1155/2016/274836727293314
   PubMed Web of Science ®Google Scholar
• Ishida T, Sakaguchi I. Protection of human keratinocytes from UVB-induced inflammation using root extract of Lithospermum erythrorhizon. Biol Pharm Bull. 2007;30:928–934. doi:10.1248/bpb.30.92817473437
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang Q, Mo W, et al. The protective effects of shikonin on hepatic ischemia/reperfusion injury are mediated by the activation of the PI3K/Akt pathway. Sci Rep. 2017;7:44785. doi:10.1038/srep4478528322249
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu T, Gan L, et al. Shikonin protects mouse brain against cerebral ischemia/reperfusion injury through its antioxidant activity. Eur J Pharmacol. 2010;643:211–217. doi:10.1016/j.ejphar.2010.06.02720599918
   PubMed Web of Science ®Google Scholar
• Kim HJ, Hwang KE, Park DS, et al. Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells. J Transl Med. 2017;15:123. doi:10.1186/s12967-017-1223-728569199
   PubMed Web of Science ®Google Scholar
• Gara RK, Srivastava VK, Duggal S, et al. Shikonin selectively induces apoptosis in human prostate cancer cells through the endoplasmic reticulum stress and mitochondrial apoptotic pathway. J Biomed Sci. 2015;22:26. doi:10.1186/s12929-015-0127-125879420
   PubMed Web of Science ®Google Scholar
• Tang JC, Ren YG, Zhao J, Long F, Chen JY, Jiang Z. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway. Life Sci. 2018;204:71–77. doi:10.1016/j.lfs.2018.05.01229738778
   PubMed Web of Science ®Google Scholar
• Li S, Zhang T, Xu W, et al. Sarcoma-targeting peptide-decorated Polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics. 2018;8:1361–1375. doi:10.7150/thno.1829929507626
   PubMed Web of Science ®Google Scholar
• Wen X, Li J, Cai D, et al. Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells. Molecules. 2018;23:268. doi:10.3390/molecules23020268
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lu B, Wang C, et al. RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species. Cancer Lett. 2017;390:77–90. doi:10.1016/j.canlet.2017.01.00428108311
   PubMed Web of Science ®Google Scholar
• Zhao Q, Kretschmer N, Bauer R, Efferth T. Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Int J Cancer. 2015;137:1446–1456. doi:10.1002/ijc.2948325688715
   PubMed Web of Science ®Google Scholar
• Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu Y. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene. 2011;30:4297–4306. doi:10.1038/onc.2011.13721516121
   PubMed Web of Science ®Google Scholar
• Liu Y, Kang X, Niu G, et al. Shikonin induces apoptosis and prosurvival autophagy in human melanoma A375 cells via ROS-mediated ER stress and p38 pathways. Artif Cells Nanomed Biotechnol. 2019;47:626–635. doi:10.1080/21691401.2019.157522930873870
   PubMed Web of Science ®Google Scholar
• Jang SY, Jang EH, Jeong SY, Kim JH. Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor. Int J Oncol. 2014;44:1455–1460. doi:10.3892/ijo.2014.230624573652
   PubMed Web of Science ®Google Scholar
• Li B, Yuan Z, Jiang J, Rao Y. Anti-tumor activity of shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway. Biosci Rep. 2018;38. doi:10.1042/BSR20181693
   Web of Science ®Google Scholar
• Chen Y, Wang T, Du J, et al. The critical role of PTEN/PI3K/AKT signaling pathway in shikonin-induced apoptosis and proliferation inhibition of chronic myeloid leukemia. Cell Physiol Biochem. 2018;47:981–993. doi:10.1159/00049014229843123
   PubMedGoogle Scholar
• Ni F, Huang X, Chen Z, Qiang W, Tong X. Shikonin exerts antitumor activity in Burkitt’s lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin. Sci Rep. 2018;8:3317. doi:10.1038/s41598-018-21570-z29463831
   PubMed Web of Science ®Google Scholar
• Zheng B, Liu F, Zeng L, et al. Overexpression of pyruvate kinase type M2 (PKM2) promotes ovarian cancer cell growth and survival via regulation of cell cycle progression related with upregulated CCND1 and downregulated CDKN1A expression. Med Sci Monit. 2018;24:3103–3112. doi:10.12659/MSM.90749029752805
   PubMed Web of Science ®Google Scholar
• You L, Zhu H, Wang C, et al. Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2. Bioorg Med Chem Lett. 2017;27:5404–5408. doi:10.1016/j.bmcl.2017.11.01129157862
   PubMed Web of Science ®Google Scholar
• Sun H, Zhu A, Zhang L, Zhang J, Zhong Z, Wang F. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma. Int J Mol Sci. 2015;16:24574–24587. doi:10.3390/ijms16102457426501265
   PubMed Web of Science ®Google Scholar
• Yan XL, Zhang XB, Ao R, Guan L. Effects of shRNA-mediated silencing of PKM2 gene on aerobic glycolysis, cell migration, cell invasion, and apoptosis in colorectal cancer cells. J Cell Biochem. 2017;118:4792–4803. doi:10.1002/jcb.2614828543190
   PubMed Web of Science ®Google Scholar
• Ao R, Guan L, Wang Y, Wang JN. Effects of PKM2 gene silencing on the proliferation and apoptosis of colorectal cancer LS-147T and SW620 cells. Cell Physiol Biochem. 2017;42:1769–1778. doi:10.1159/00047945628746922
   PubMedGoogle Scholar
• Zhao H, Han L, Jian Y, et al. Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis. Onco Targets Ther. 2018;11:8995–9006. doi:10.2147/OTT30588012
   PubMed Web of Science ®Google Scholar
• Yao A, Xiang Y, Si Y, et al. PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells. J Cell Biochem. 2019;120:6542–6554. doi:10.1002/jcb.2794730368881
   PubMed Web of Science ®Google Scholar
• Chen J, Yu Y, Chen X, et al. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma. Cell Prolif. 2018;51:e12510. doi:10.1111/cpr.2018.51.issue-630105813
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhu Y, Hu J, et al. Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic glycolysis. Sci Rep. 2018;8:14517. doi:10.1038/s41598-018-31615-y30266938
   PubMed Web of Science ®Google Scholar
• Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma. 2019;6:31–39. doi:10.2147/JHC.S16895330775342
   PubMed Web of Science ®Google Scholar
• Li YL, Hu X, Li QY, et al. Shikonin sensitizes wildtype EGFR NSCLC cells to erlotinib and gefitinib therapy. Mol Med Rep. 2018;18:3882–3890. doi:10.3892/mmr.2018.934730106133
   PubMed Web of Science ®Google Scholar
• Liu X, Sun G. Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells. Oncol Lett. 2017;14:4270–4276. doi:10.3892/ol.2017.670228943938
   PubMed Web of Science ®Google Scholar
• Song J, Zhao Z, Fan X, et al. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo. Oncotarget. 2016;7:70504–70515. doi:10.18632/oncotarget.1204127655700
   PubMedGoogle Scholar